Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

On Monday, former four-star BYU linebacker Aisea Moa committed to the Michigan State Spartans, as reported by On3's Jason Killop. Moa and his family (including high four-star offer Salesi ...

MoA International Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's superior long-term risk-adjusted performance, as shown by the firm's average 10 ...

The profitability screen requires that the sum of a company’s GAAP earnings over the past four quarters be positive as well as the most recent quarter. The screen imparts a slight quality tilt ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

Statistics show that obstructive sleep apnea (OSA) is a common disorder affecting around 30 million adults in the US. In a recent press release, the American Food and Drug Administration has ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES REAL ESTATE CLASSIFIEDS EVENTS PETS CONTACT US ADVERTISING ...